Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy-A comprehensive cancer center experience

被引:7
|
作者
Zhang, Zhen [1 ,2 ]
Sharma, Rajeev [1 ,2 ]
Hamad, Lamya [1 ,2 ]
Riebandt, Grazyna [1 ,2 ]
Attwood, Kristopher [1 ,3 ]
机构
[1] Roswell Pk Comprehens Canc Ctr, Div Endocrinol Diabet & Metab, 665 Elm St, Buffalo, NY 14203 USA
[2] Dept Med, Buffalo, NY 14203 USA
[3] Dept Biostat & Bioinformat, Buffalo, NY 14203 USA
关键词
Immune checkpoint inhibitors; Immune-related adverse events; Diabetes; Endocrinopathy;
D O I
10.1016/j.diabres.2023.110776
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and more patients are receiving ICIs than before. Although this has improved cancer care but so has the increase in the incidence of immune-related adverse events (irAEs) including endocrinopathies. ICI-induced diabetes mellitus (DM) is a rare irAE with an approximate incidence of 1%. Due to paucity of data in literature about ICI-induced DM, we conducted a study to report the incidence and characteristics of new onset and worsening of DM in patients treated with ICIs. Methods: We conducted a retrospective review of patients who received ICIs during 10-year period. We identified patients with newly diagnosed DM and worsening of preexisting DM. Findings: Among 2,477 patients who received one or multiple ICIs, 14 patients developed new onset DM and 11 patients experienced worsening of pre-existing DM. Median time to new onset or worsening DM from ICI treatment initiation was similar to 12 weeks. Median hemoglobin A1c was 6.2% at baseline and 8.5% at the onset of ICIinduced DM. Seven patients presented with diabetes ketoacidosis (DKA), all in the new onset group. (p = 0.02) No significant difference was observed between two groups regarding personal history of autoimmune disorder or family history of DM. (p greater than 0.05) Positive autoantibodies were found in three patients [two with Glutamic Acid Decarboxylase (GAD65) antibodies and one with insulin autoantibodies (IAA)]. Interpretation: The incidence of new onset and worsening DM in patients treated with ICIs was 1.01%.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Improved Outcome for Immune Checkpoint Inhibitors (ICI) in Patients Previously Treated with Bavituximab in the SUNRISE Trial
    Boyer, M.
    Spigel, D.
    Mainwaring, P.
    Lena, H.
    Mccleod, M.
    Losonczy, G.
    Sanborn, R.
    Natale, R.
    Tang, M.
    Lai, J.
    Kallinteris, N.
    Shan, J.
    Gerber, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1840 - S1841
  • [32] CLINICAL FEATURES AND OUTCOMES OF CARDIAC INVOLVEMENT IN PATIENTS WITH CANCER TREATED WITH IMMUNE CHECKPOINT INHIBITORS <ICI>
    Abou Alaiwi, Sarah
    Nassar, Amin
    Zarif, Talal
    El-Am, Edward
    Denu, Ryan
    Macaron, Walid
    Malvar, Carmel
    Cortellini, Alessio
    Korolewicz, James
    Sackstein, Paul
    Nana, Frank Aboubakar
    Woodford, Rachel
    Long, Georgina V.
    Kwan, Jennifer
    Grynberg, Shirly
    Shapira, Ronnie
    Herrera-Juarez, Mercedes
    Foderaro, Simone
    Vasbinder, Alexi
    Asnani, Aarti
    Tandon, Ankita
    Hayek, Salim
    Neilan, Tomas G.
    Choueiri, Toni
    Naqash, Abdul-Rafeh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2353 - 2353
  • [33] The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy
    Jackson-Carroll, Natalie
    Johnson, Constance
    Tawbi, Hussein
    Wang, Xin Shelley
    Whisenant, Meagan
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [34] Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
    Dokmetas, Meric
    Muglu, Harun
    Ozcan, Erkan
    Kuvvet, Buket Bayram
    Helvaci, Kaan
    Kalaci, Ender
    Kahraman, Seda
    Aykan, Musa Baris
    Cicin, Irfan
    Selcukbiricik, Fatih
    Olmez, Omer Fatih
    Bilici, Ahmet
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [35] REAL-WORLD INCIDENCE AND IMPACT OF PNEUMONITIS IN LUNG CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
    Tiu, Bruce
    Zubiri, Leyre
    Iheke, James
    Pahalyants, Vartan
    Theodosakis, Nicholas
    Ugwu-Dike, Pearl
    Seo, Jayhyun
    Tang, Kimberly
    Sullivan, Ryan
    Mooradian, Meghan
    Semenov, Yevgeniy
    Reynolds, Kerry
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A841 - A841
  • [36] Incidence of adrenal insufficiency in patients with solid malignancies treated with immune checkpoint inhibitors
    Archambault, Alexi
    Wang, Juan
    Byrne, Shauna
    Gullo, Giuseppe
    Hampp, Christian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 233 - 233
  • [37] Incidence of Cardiotoxicity in Patients Treated for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
    Carpenter, I. N.
    Brice, K. B.
    Walker, D.
    Dumais, K.
    Alvarez, A. M.
    Cohen, N. S.
    Raez, L. E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S629 - S629
  • [38] Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience
    Nardo, Mirella
    Yilmaz, Bulent
    Nelson, Blessie Elizabeth
    Torres, Harrys A.
    Wang, Lan Sun
    Granwehr, Bruno Palma
    Song, Juhee
    Dalla Pria, Hanna R. F.
    Trinh, Van A.
    Glitza Oliva, Isabella C.
    Patel, Sapna P.
    Tannir, Nizar M.
    Kaseb, Ahmed Omar
    Altan, Mehmet
    Lee, Sunyoung S.
    Miller, Ethan
    Zhang, Hao
    Stephen, Bettzy A.
    Naing, Aung
    ONCOLOGIST, 2023, : 714 - 721
  • [39] A Quarter of Patients Treated with Checkpoint Inhibitors Develop Immune-Related Adverse Events: A University Center Experience
    Zhou, Celine
    Elg-Salsman, Whitney
    Kiwalkar, Sonam
    Sathe, Nishad
    Friedman, Marcia
    Deodhar, Atul
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [40] Severe irAEs in patients with immune checkpoint inhibitor therapy: Experience in a Mexican cancer center.
    Molina, Diana Bonilla
    Nehmad, Cecilia
    Cabrera, Juan Manuel Tovar
    Lopez, Ervin Saul Enciso
    Sanchez, Efrain Isaias Camarin
    Gerson, Daniela Shveid
    Rodriguez, Benigno
    Villamayor, Omar Serrano
    Zepeda, Lorena Lopez
    Vazquez, Yazmin Carolina Blanco
    Limas, Christian Patricio Camacho
    Martinez-Herrera, Jose Fabian
    Olivares, Guillermo
    Cwilich, Raquel Gerson
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)